Molecular imaging has proven to be a powerful tool for investigation of parkinsonian disorders. One current challenge is to identify biomarkers of early changes that may predict the clinical trajectory of parkinsonian disorders. Exciting new tracer developments hold the potential for in vivo markers of underlying pathology. Herein, the authors provide an overview of molecular imaging advances and how these approaches help us to understand PD and atypical parkinsonisms.
Every physiotherapist will work with someone who has had a stroke during their career. Gain a deeper understanding based on the latest evidence and become a better clinician.